Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

A composition comprising:

• at least a first mRNA construct comprising at least one a first open reading frame (ORF), wherein the first ORF encodes a tumor antigen;
• at least a second mRNA construct comprising at least a second open reading frame (ORF), wherein the second ORF encodes a product associated with vaccine induced immunity selected from the group consisting of:
• IL-1;
• IL-2;
• IL-3;
• IL-4;
• IL-5;
• IL-6;
• IL-7;
• IL-8;
• IL-9;
• IL-10;
• IL-11;
• IL-12;
• IL-15;
• IL-17;
• IL-21;
• TGF-beta;
• IFNγ;
• IFNα;
• IFNβ;
• TNFα;
• M-CSF;
• G-CSF;
• GM-CSF;
• CCL2;
• CCL3;
• CCL4;
• CCL5;
• CCL20;
• CCL22;
• CCL28;
• CXCL8;
• CXCL9;
• CXCL10;
• CXCL11;
• CXCL12;
• and XCL1 and wherein the second ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least a first, second, and a third micro-RNA (miRNA) target sequence, and wherein each of the at least first, second, and third miRNA target sequences are optimised to each hybridise with a different corresponding miRNA sequence;
• and
• an in vivo delivery composition;
• wherein the first and second mRNA constructs are comprised within or adsorbed to the delivery composition.